glycine has been researched along with Lymphoma, T Cell, Peripheral in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ixazomib is an investigational proteasome inhibitor that has shown preclinical activity in lymphoma models." | 2.79 | Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. ( Assouline, SE; Chang, J; Cheson, BD; Di Bacco, A; Gupta, N; Hamburg, S; Hui, AM; Martin, P; Reyes, R; Rifkin, R; Shou, Y; Yu, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boonstra, PS | 1 |
| Polk, A | 1 |
| Brown, N | 1 |
| Hristov, AC | 1 |
| Bailey, NG | 1 |
| Kaminski, MS | 1 |
| Phillips, T | 1 |
| Devata, S | 1 |
| Mayer, T | 1 |
| Wilcox, RA | 1 |
| Assouline, SE | 1 |
| Chang, J | 1 |
| Cheson, BD | 1 |
| Rifkin, R | 1 |
| Hamburg, S | 1 |
| Reyes, R | 1 |
| Hui, AM | 1 |
| Yu, J | 1 |
| Gupta, N | 1 |
| Di Bacco, A | 1 |
| Shou, Y | 1 |
| Martin, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic[NCT03683277] | Phase 2 | 26 participants (Actual) | Interventional | 2019-11-03 | Terminated (stopped due to Recruitment issue, 26 patients enrolled instead of 70 initially planned) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for glycine and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.
Topics: Aged; Boron Compounds; Cell Line, Tumor; Female; GATA3 Transcription Factor; Glycine; Humans; Lympho | 2017 |
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
Topics: Adult; Aged; Boron Compounds; Diarrhea; Female; Glycine; Humans; Lymphoma, Follicular; Lymphoma, T-C | 2014 |